Immunic, Inc. (NASDAQ:IMUX) Receives $12.67 Consensus PT from Analysts

Immunic, Inc. (NASDAQ:IMUX) has earned a consensus recommendation of “Buy” from the eight analysts that are presently covering the company, MarketBeat reports. Six investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $12.67.

Several research firms have issued reports on IMUX. D. Boral Capital reissued a “buy” rating and set a $17.00 price target on shares of Immunic in a report on Tuesday, January 7th. StockNews.com downgraded Immunic from a “hold” rating to a “sell” rating in a research note on Monday, November 11th. Finally, HC Wainwright began coverage on shares of Immunic in a research note on Monday, November 25th. They set a “buy” rating and a $10.00 target price on the stock.

Insider Activity at Immunic

In related news, Director Richard Alan Rudick bought 87,300 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The stock was bought at an average cost of $1.15 per share, with a total value of $100,395.00. Following the completion of the purchase, the director now owns 87,300 shares of the company’s stock, valued at approximately $100,395. The trade was a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. 3.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in IMUX. Virtu Financial LLC bought a new stake in shares of Immunic in the third quarter worth about $50,000. HB Wealth Management LLC bought a new stake in Immunic in the 4th quarter worth approximately $81,000. Jane Street Group LLC raised its holdings in shares of Immunic by 121.4% during the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after acquiring an additional 38,553 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Immunic by 70.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock valued at $169,000 after acquiring an additional 42,383 shares during the last quarter. Finally, State Street Corp grew its holdings in shares of Immunic by 7.5% in the third quarter. State Street Corp now owns 167,145 shares of the company’s stock valued at $276,000 after purchasing an additional 11,642 shares in the last quarter. Institutional investors own 51.82% of the company’s stock.

Immunic Price Performance

Shares of IMUX stock opened at $0.95 on Friday. Immunic has a 1 year low of $0.95 and a 1 year high of $2.11. The firm has a fifty day moving average price of $1.11 and a 200-day moving average price of $1.31.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.